MANE Company Profile and Key Details

NYSE : MANE

Veradermics

$63.49

1.57+2.54%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Veradermics, Incorporated (MANE) stock surged +2.54%, trading at $63.49 on NYSE, up from the previous close of $61.92. The stock opened at $62.53, fluctuating between $62.53 and $66.20 in the recent session.

Stock Snapshot

61.92

Prev. Close

2.23B

Market Cap

62.53

Day Low

-19.07

P/E Ratio

-3.33

EPS (TTM)

N/A

Cash Flow per Share

62.53

Open

35.08M

Number of Shares

66.1999

Day High

N/A

Free Float in %

N/A

Book Value

538.66K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 24, 2026	62.53	66.20	62.53	63.49	536.79K
Mar 23, 2026	59.01	62.86	58.96	61.92	291.83K
Mar 20, 2026	55.70	59.61	55.05	58.89	1.32M
Mar 19, 2026	57.88	59.60	55.00	56.91	620.39K
Mar 18, 2026	60.50	63.03	58.40	59.01	530.91K
Mar 17, 2026	56.45	62.56	55.99	61.07	573.33K
Mar 16, 2026	52.62	58.60	52.62	56.95	339.95K
Mar 13, 2026	51.75	54.65	51.75	52.80	272.58K
Mar 12, 2026	51.20	57.08	50.00	51.57	414.34K
Mar 11, 2026	50.70	52.41	49.89	51.03	147.78K
Mar 10, 2026	51.35	53.63	49.00	50.65	276.36K
Mar 09, 2026	48.93	52.60	48.93	51.32	466.35K
Mar 06, 2026	48.52	51.03	47.14	48.56	305.7K
Mar 03, 2026	44.36	47.40	43.76	45.08	182.96K
Mar 02, 2026	46.99	50.86	46.01	46.62	221.32K
Feb 27, 2026	42.58	45.88	42.58	45.85	279.36K
Feb 26, 2026	42.17	43.73	41.56	42.91	160.78K
Feb 25, 2026	44.45	44.74	39.73	42.17	433.1K
Feb 24, 2026	44.98	45.53	43.28	43.79	212.97K
Feb 23, 2026	44.28	45.90	42.51	45.00	244.31K

Contact Details

New Haven, CT 06513

United States

https://www.veradermics.com 228 372 3376

About Company

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.

Stock Peers

AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 EVMN

-2.43-10.36%

Evommune, Inc.$21.02 RCUS

-1.16-5.42%

Arcus Biosciences, Inc.$20.25 ANRO

0.17+0.85%

Alto Neuroscience, Inc.$20.19 BHVN

-0.35-4.00%

Biohaven Ltd.$8.39 DNA

0.18+2.58%

Ginkgo Bioworks Holdings, Inc.$7.17 BTX

0.05+0.76%

BlackRock Technology and Private Equity Term Trust$6.65 NUVB

-0.07-1.61%

Nuvation Bio Inc.$4.28 ADCT

-0.11-2.72%

ADC Therapeutics S.A.$3.94 ANVS

-0.13-5.20%

Annovis Bio, Inc.$2.37

Company Overview

Veradermics, Incorporated (NYSE:MANE) closed at $63.49 USD, gaining $1.57 (2.54%) from the previous close of $61.92. The stock is currently within 5% of its 52-week high $32.00 and $66.20. With a market capitalization of about $2.23 billion, Veradermics, Incorporated is classified as a mid-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 451.85 thousand shares, in line with its 52-week average. Headquartered in New Haven, CT, Veradermics, Incorporated operates in the Healthcare sector and the Biotechnology industry. Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.06%, SMA50 -0.06%, SMA200 -0.06%). The stock’s 14-day RSI is 59.28 (neutral), while the ATR of 4.21 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -16.78% below its high and over 34.09% above its low. Average 10-day trading volume of 602.46 thousand shares is significantly above the 3-month average of 358.74 thousand, indicating heightened recent market interest.

Valuation Metrics

Veradermics, Incorporated trades at a P/E ratio of -488.89, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 236.89 reflecting a rich premium to book value. The P/FCF stands at -95.24, also below market averages. Compared to sector medians, Veradermics, Incorporated P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Veradermics, Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $85.00 to $75.00. The high target offers 33.88% upside. The low target suggests 18.13% downside. The mean target is $78.33. This offers 23.37% upside.

Financial & Profitability Overview

Over the trailing twelve months, Veradermics has not generated any revenue.
On valuation metrics, Veradermics trades at a P/E of -488.89, P/S of 0.00 and P/B of 236.89. The current ratio is 11.77 and quick ratio is 11.77.

Price Forecast & Outlook

Our AI price prediction model suggests that Veradermics, Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.6%, with price expected at $71.49 by April 07, 2026, within a range of $68.39 to $74.82 3-Month Outlook: Projected rise of 6.65%, reaching $67.71 by June 22, 2026, with a range of $67.49 to $67.94. 1-Year Outlook: Projected gain of 1071.13%, with price at $743.55 by March 24, 2027, within a range of $743.13 to $743.93.

Key Takeaways

currently trading near 52-week highs band. Valuation shows Veradermics, Incorporated trading at a premium to the broader market with a P/E of -488.89. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $78.33, suggesting 23.37% upside. Our AI forecast model points to short-term strength (12.6% over two weeks), a medium-term rise (6.65% over three months), and a longer-term gain (1071.13% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Veradermics, Incorporated (MANE) stock price?

Veradermics, Incorporated (NYSE: MANE) stock price is $63.49 in the last trading session. During the trading session, MANE stock reached the peak price of $66.20 while $62.53 was the lowest point it dropped to. The percentage change in MANE stock occurred in the recent session was 2.54% while the dollar amount for the price change in MANE stock was $1.57.

MANE's industry and sector of operation?

The NYSE listed MANE is part of Biotechnology industry that operates in the broader Healthcare sector. Veradermics, Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MANE?

No Data

How MANE did perform over past 52-week?

MANE's closing price is 98.41% higher than its 52-week low of $32.00 where as its distance from 52-week high of $66.20 is -4.09%.

How many employees does MANE have?

Number of MANE employees currently stands at 0.

Link for MANE official website?

Official Website of MANE is: https://www.veradermics.com

How do I contact MANE?

MANE could be contacted at phone 228 372 3376 and can also be accessed through its website. MANE operates from 470 James Street, New Haven, CT 06513, United States.

How many shares of MANE are traded daily?

MANE stock volume for the day was 538.66K shares. The average number of MANE shares traded daily for last 3 months was 451.85K.

What is the market cap of MANE currently?

The market value of MANE currently stands at $2.23B with its latest stock price at $63.49 and 35.08M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	0
Beta	0
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MANE Company Profile and Key Details

Veradermics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Earnings & Analyst Outlook

Price Forecast & Outlook

Financial & Profitability Overview

Key Takeaways

Dividend & Fair Value

Company Overview

Valuation Metrics